Sudden cardiac death

Czech version

Authors: M. Mikolášková ¹; M. Sepši ¹; J. Špinar ^1,2
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno ¹; Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně ²
Published in: Kardiol Rev Int Med 2015, 17(2): 106-111
Category: Cardiology Review

Overview

Sudden cardiac death (cardiac death) is defined as death from cardiac causes occurring within one hour of the onset of symptoms wherein the time and course of death are unforeseen. In 80% of cases sudden cardiac death occurs as a result of malignant arrhythmias – ventricular fibrillation and sustained ventricular tachycardia mostly associated with structural heart disease. Current stratification methods allow identifying the patients at risk of sudden cardiac death in groups with clearly defined heart disease. There are no stratification methods for the general population. Unexpected causes of this disease creates a need for discovering new methods which would lead to more effective prevention and identification of patients at risk.

Keywords:
sudden cardiac death – primary prevention – risk stratification – implantable cardioverter-defibrillator – arrhythmia

Sources

1. Hinkle LE Jr. The immediate antecedents of sudden death. Acta Med Scand Suppl 1981; 210: 207– 217.

2. Chugh SS, Ji J, Gunson K et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate‑based review in a large U.S. community. J Am Coll Cardiol 2004; 44: 1268– 1275.

3. Chugh SS, Reinier K, Teodorescu C et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008; 51: 213– 228. doi: 10.1016/ j.pcad.2008.06.003.

4. Huikuri H, Castellanos A, Myerburg R. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473– 1482.

5. Křivan L. Náhlá srdeční smrt: Jak ji předcházet. Kardiol Rev 2006; 8: 20– 24.

6. Maron BJ et al. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles. JAMA 1996; 276: 199– 204.

7. Angelini P, Velasco JA, Flamm S. Coronary anomalies: incidence, pathophysiology, and clinical relevance. Circulation 2002; 105: 2449– 2454.

8. Jabbari R, Risgaard B, Holst AG et al. Cardiac symptoms before sudden cardiac death caused by coronary artery disease a nationwide study among young Danish people. Heart 2013; 99: 938– 943. doi: 10.1136/ heartjnl‑ 2012‑ 303534.

9. Coumel P, Fidelle J, Lucet V et al. Catecholaminergic induced severe ventricular arrhythmias with Adams‑ Stokes syndrome in children: report of four cases. Br Heart J 1978; 40 (Suppl): 28– 37.

10. Priori SG, Napolitano C, Memmi M et al. Clinical and molecular characterization of patiens with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69– 74.

11. Antzelevitch C, Brugada P, Borggrefe M et al. Brugada syndrome: report of the second konsensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659– 670.

12. Saksena S, Madan N. Management of the patient with an implantable cardioverter – defibrillator in the third millennium. Circulation 2002; 106: 2642– 2646.

13. Zipes DP, Camm AJ, Borggrefe M et al. ACC/ AHA/ ESC 2006 guidelines for management of patiens with ventricular arrhythmias and the preventiv of sudden cardiac death. Europace 2006; 8: 746– 837.

14. Meissner MD, Morganroth J. Silent myocardialischemia as a mechanismofcardiac death. Cardiol Clin 1986; 4: 593– 605.

15. Berger CJ, Murabito JM, Evans JC et al. Prognosis after first myocardial infarction: comparison of Q‑ wave and non‑Q‑ wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268: 1545– 1551.

16. Solomon SD, Zelenkofske S, McMurray JJ et al. Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352: 2581– 2588.

17. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010; 375: 752– 762.

18. Felker GM, Thompson RE, Hare JM et al. Underlying causes and long‑term survival in patiens with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077– 1084.

19. Goldberger JJ, Buxton AE, Cain M et al. Risk stratification for arrhythmic sudden cardiac death: identifying the road blocks. Circulation 2011; 123: 2423– 2430. doi: 10.1161/ CIRCULATIONAHA.110.959734.

20. Maron MS, Appelbaum E, Harrigan CJ et al. Clinical profile and signifikance of playe denhancement in hypertrophic cardiomyopathy. Circulation 2008; 1: 184– 191. doi: 10.1161/ CIRCHEART FAILURE.108.768119.

21. Táborský M, Kautzner J, Bytešník J et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů‑ defibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 51: 602– 618.

22. Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335: 1933– 1940.

23. Buxton AE, Lee KL, Fisher JD et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882– 1890.

24. Moss AJ, Zareba W, Hall WJ et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877– 883.

25. Hohnloser SH, Kuck KH, Dorian P et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverter‑ defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481– 2488.

26. Steinbeck G, Andresen D, Seidl K et al. IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009; 361: 1427– 1436. doi: 10.1056/ NEJMoa0901889.

27. Ottervanger JP, Ramdat Misier AR, Dambrink JH et al. Zwolle Myocardial Infarction Study Group. Mortality in patients with left ventricular ejection fraction

28. Myerburg RJ, Mitrani R, Interian A Jr et al. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998; 97: 1514– 1521.

29. Gorgels AP, Gijsbers C, de Vreede‑ Swagemakers Jet al. Out‑ of‑ hospital cardiac arrest the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204– 1209.

30. Stecker EC, Vickers C, Waltz J et al. Population‑based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two‑year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47: 1161– 1166.

31. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an implantable cardioverter‑ defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225– 237.

32. Roes SD, Borleffs CJ, van der Geest RJ et al. Infarct tissue heterogeneity assessed with contrast‑ enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter‑ defibrillator. Circ Cardiovasc Imaging 2009; 2: 183– 190. doi: 10.1161/ CIRCIMAGING.108.826529.

33. Camm AJ, Pratt CM, Schwartz PJ et al. AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo‑ controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109: 990– 996.

34. Huikuri HV, Raatikainen MJ, Moerch‑ Joergensen R et al. Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction study group. Prediction of fatal or near‑ fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J 2009; 30: 689– 698. doi: 10.1093/ eurheartj/ ehn537.

35. Pastore JM, Laurita KR, Rosenbaum DS. Importance of spatiotemporal heterogenity of cellular restitution in mechanism of arrhythmogenic discordant alternans. Heart Rhythm 2006; 3: 711– 719.

36. Ikeda T, Saito H, Tanno K et al. T wave alternans as a predictor for sudden death after myocardial infarction. Am J Cardiol 2002; 89: 79– 82.

37. Josephson M, Hein J, Wellens J. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109: 2685– 2691.

38. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patiens receiving encanaide, flecanaide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781– 788.

39. The Cardiac Arrhytmia Suppression Trial II Incestigators. Effect of the antiarrhytmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227– 233.

40. Waldo A, Camm AJ, deRuyter H et al. Effectof d‑ sotalol on mortality in patiens with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7– 12.

41. Massie BM, Fisher SG, Deedwania PC et al. Effect of amiodarone on clinical status and left ventricular function in patiens with congestive heart failure. Circulation 1996; 93: 2128– 2134.

42. Schmidt G, Malik M, Barthel P et al. Heart‑ rate turbulence after ventricular premature beats as a predátor of mortality after acute myocardial infarction. Lancet 1999; 353: 1390– 1396.

43. Bauer A, Guzik P, Barthel P et al. Reduced prognostic power of ventricular late potentials in post‑infarction patients of the reperfusion era. Eur Heart J 2005; 26: 755– 761.

44. Bourke JP et al. Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow‑up: results, optimal stimulation protocol and cost‑effec-tive screening. J Am Coll Cardiol 1991; 18: 780– 788.

45. Exner VD, Kavanagh KM, Slawnych MP et al. Noninvasive risk assessment early after a myocardial infarcti. J Am Coll Cardiol 2007; 24: 2275– 2284.

46. Bytešník J, Pařízek P, Wichterle D et al. Komorové arytmie. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2011; 53 (Suppl 1): 53– 77.